vs
Pediatrix Medical Group, Inc.（MD）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
SCANSOURCE, INC.的季度营收约是Pediatrix Medical Group, Inc.的1.6倍（$766.5M vs $493.8M），Pediatrix Medical Group, Inc.净利率更高（6.8% vs 2.2%，领先4.7%），SCANSOURCE, INC.同比增速更快（2.5% vs -1.7%），过去两年SCANSOURCE, INC.的营收复合增速更高（0.9% vs -0.1%）
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
MD vs SCSC — 直观对比
营收规模更大
SCSC
是对方的1.6倍
$493.8M
营收增速更快
SCSC
高出4.3%
-1.7%
净利率更高
MD
高出4.7%
2.2%
两年增速更快
SCSC
近两年复合增速
-0.1%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $493.8M | $766.5M |
| 净利润 | $33.7M | $16.5M |
| 毛利率 | — | 13.4% |
| 营业利润率 | 9.9% | 2.3% |
| 净利率 | 6.8% | 2.2% |
| 营收同比 | -1.7% | 2.5% |
| 净利润同比 | 10.5% | -3.3% |
| 每股收益（稀释后） | $0.40 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDSCSC
| Q4 25 | $493.8M | $766.5M | ||
| Q3 25 | $492.9M | $739.6M | ||
| Q2 25 | $468.8M | $812.9M | ||
| Q1 25 | $458.4M | $704.8M | ||
| Q4 24 | $502.4M | $747.5M | ||
| Q3 24 | $511.2M | $775.6M | ||
| Q2 24 | $504.3M | $746.1M | ||
| Q1 24 | $495.1M | $752.6M |
净利润MDSCSC
| Q4 25 | $33.7M | $16.5M | ||
| Q3 25 | $71.7M | $19.9M | ||
| Q2 25 | $39.3M | $20.1M | ||
| Q1 25 | $20.7M | $17.4M | ||
| Q4 24 | $30.5M | $17.1M | ||
| Q3 24 | $19.4M | $17.0M | ||
| Q2 24 | $-153.0M | $16.1M | ||
| Q1 24 | $4.0M | $12.8M |
毛利率MDSCSC
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 13.0% | ||
| Q1 24 | — | 12.6% |
营业利润率MDSCSC
| Q4 25 | 9.9% | 2.3% | ||
| Q3 25 | 13.8% | 3.5% | ||
| Q2 25 | 12.8% | 3.3% | ||
| Q1 25 | 7.0% | 3.2% | ||
| Q4 24 | 7.8% | 2.5% | ||
| Q3 24 | 6.6% | 2.3% | ||
| Q2 24 | -31.3% | 2.9% | ||
| Q1 24 | 3.2% | 2.3% |
净利率MDSCSC
| Q4 25 | 6.8% | 2.2% | ||
| Q3 25 | 14.5% | 2.7% | ||
| Q2 25 | 8.4% | 2.5% | ||
| Q1 25 | 4.5% | 2.5% | ||
| Q4 24 | 6.1% | 2.3% | ||
| Q3 24 | 3.8% | 2.2% | ||
| Q2 24 | -30.3% | 2.2% | ||
| Q1 24 | 0.8% | 1.7% |
每股收益（稀释后）MDSCSC
| Q4 25 | $0.40 | $0.75 | ||
| Q3 25 | $0.84 | $0.89 | ||
| Q2 25 | $0.46 | $0.87 | ||
| Q1 25 | $0.24 | $0.74 | ||
| Q4 24 | $0.37 | $0.70 | ||
| Q3 24 | $0.23 | $0.69 | ||
| Q2 24 | $-1.84 | $0.66 | ||
| Q1 24 | $0.05 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $375.2M | $83.5M |
| 总债务越低越好 | $570.5M | — |
| 股东权益账面价值 | $865.9M | $910.9M |
| 总资产 | $2.2B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.66× | — |
8季度趋势，按日历期对齐
现金及短期投资MDSCSC
| Q4 25 | $375.2M | $83.5M | ||
| Q3 25 | $340.1M | $124.9M | ||
| Q2 25 | $224.7M | $126.2M | ||
| Q1 25 | $99.0M | $146.3M | ||
| Q4 24 | $229.9M | $110.5M | ||
| Q3 24 | $103.8M | $145.0M | ||
| Q2 24 | $19.4M | $185.5M | ||
| Q1 24 | $8.0M | $159.1M |
总债务MDSCSC
| Q4 25 | $570.5M | — | ||
| Q3 25 | $577.2M | — | ||
| Q2 25 | $583.9M | — | ||
| Q1 25 | $590.5M | — | ||
| Q4 24 | $597.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MDSCSC
| Q4 25 | $865.9M | $910.9M | ||
| Q3 25 | $890.7M | $914.0M | ||
| Q2 25 | $833.8M | $906.4M | ||
| Q1 25 | $789.2M | $901.7M | ||
| Q4 24 | $764.9M | $900.7M | ||
| Q3 24 | $732.5M | $920.9M | ||
| Q2 24 | $706.5M | $924.3M | ||
| Q1 24 | $856.2M | $944.1M |
总资产MDSCSC
| Q4 25 | $2.2B | $1.7B | ||
| Q3 25 | $2.2B | $1.7B | ||
| Q2 25 | $2.1B | $1.8B | ||
| Q1 25 | $2.0B | $1.7B | ||
| Q4 24 | $2.2B | $1.7B | ||
| Q3 24 | $2.1B | $1.8B | ||
| Q2 24 | $2.0B | $1.8B | ||
| Q1 24 | $2.2B | $1.8B |
负债/权益比MDSCSC
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.1M | $30.8M |
| 自由现金流经营现金流 - 资本支出 | — | $28.9M |
| 自由现金流率自由现金流/营收 | — | 3.8% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | 3.39× | 1.87× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MDSCSC
| Q4 25 | $114.1M | $30.8M | ||
| Q3 25 | $137.3M | $23.2M | ||
| Q2 25 | $137.2M | — | ||
| Q1 25 | $-117.5M | $66.1M | ||
| Q4 24 | $133.0M | $-6.2M | ||
| Q3 24 | $91.8M | $44.8M | ||
| Q2 24 | $107.0M | — | ||
| Q1 24 | $-125.2M | $160.2M |
自由现金流MDSCSC
| Q4 25 | — | $28.9M | ||
| Q3 25 | — | $20.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.6M | ||
| Q4 24 | — | $-8.2M | ||
| Q3 24 | — | $42.5M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $157.7M |
自由现金流率MDSCSC
| Q4 25 | — | 3.8% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 9.2% | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 21.0% |
资本支出强度MDSCSC
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.3% |
现金转化率MDSCSC
| Q4 25 | 3.39× | 1.87× | ||
| Q3 25 | 1.91× | 1.17× | ||
| Q2 25 | 3.49× | — | ||
| Q1 25 | -5.66× | 3.79× | ||
| Q4 24 | 4.36× | -0.36× | ||
| Q3 24 | 4.72× | 2.64× | ||
| Q2 24 | — | — | ||
| Q1 24 | -31.03× | 12.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
